SCIENCE TRIBUNE
The KBO register records legal situation 013 for SCIENCE TRIBUNE (Register: dissolution or liquidation); this is today's state according to the register itself, which carries no start date. The 2023 annual accounts show equity of €272k and a net result of €190k.
| Equity | €272k |
| Net result | €190k |
| Better than sector | 37% |
| Active | 18 yrs |
Strong profile, led by profitability.
All 5 axes are computed from data Checked has read.
Dissolution or liquidation
The KBO register records that this company is being wound up. A twelve-month bankruptcy probability no longer says anything in that case, so we show no figure.
Unlock the full score breakdown, per-year score history and the indicative credit limit with Plus.
See plans →| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 15.3% | 26.4% | |
| Net result | €190k | €24k | |
| Equity | €272k | €157k | |
| Gross operating margin | €237k | €179k | |
| Total assets | €1.78M | €921k |
| Fiscal year | 2023 |
|---|---|
| Deposit | verkort |
| Revenue | - |
| EBITDA | €237k |
| Net profit | €190k |
| Cash flow | €218k |
| Staff costs | - |
| Income taxes | - |
| Dividends | - |
| Total assets | €1.78M |
| Equity | €272k |
| Debt | €1.51M |
| of which ≤ 1y | €1.36M |
| of which > 1y | €143k |
| Working capital | €158k |
| Employees (FTE) | - |
| 2023 | |
|---|---|
| Current ratio | 1.12 |
| Quick ratio | 1.12 |
| Working capital ratio | 8.9% |
| Solvency | 15.3% |
| Debt / equity | 5.55 |
| Long-term debt ratio | 0.52 |
| Interest coverage | 12.82 |
| Gross margin | - |
| Net margin | - |
| ROA | 10.7% |
| ROE | 69.7% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2023 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €1.78M |
| Fixed assets | 21/28 | €262k |
| Intangible fixed assets | 21 | €257k |
| Financial fixed assets | 28 | €6k |
| Current assets | 29/58 | €1.52M |
| Amounts receivable within one year | 40/41 | €1.33M |
| Cash & bank | 54/58 | €177k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €1.78M |
| Equity | 10/15 | €272k |
| Contributions / capital | 10/11 | €494k |
| Reserves | 13 | €12k |
| Accumulated profits (losses) | 14 | €-234k |
| Amounts payable | 17/49 | €1.51M |
| Amounts payable after one year | 17 | €143k |
| Amounts payable within one year | 42/48 | €1.36M |
| Income statement | ||
| Gross operating margin | 9900 | €237k |
| Operating result | 9901 | €208k |
| Financial income | 75 | €125 |
| Financial charges | 65 | €18k |
| Result before taxes | 9903 | €190k |
| Net result for the period | 9904 | €190k |
| Result to be appropriated | 9905 | €190k |
-
Inge BerckmansDirectorState Gazette act 22133218 (10-11-2022)Current10-11-2022 → present
-
Olaf BeckersDirectorState Gazette act 22133218 (10-11-2022)Current10-11-2022 → present
-
Peter GoossensManaging directorState Gazette act 22133218 (10-11-2022)Current10-11-2022 → present
| NACE primary | Wholesale trade(46180) |
| Legal form | Public limited company(014) |
| Incorporation | 23-10-2007 |
| Status | Active |
| Postal code | 3900 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 72502E0102/00R133 | Flanders | 4,707 m² | 1 · 1,348 m² | 8.5 m · 2 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
23-11-2023 Capital increase of €160,000 to €494,000
- €334.000 → €494.000
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 494000.0,
"delta_eur": 160000.0,
"before_eur": 334000.0,
"subscribers": [
{
"kbo": null,
"rrn": null,
"kind": "person",
"name": "GOOSSENS Peter",
"share_class": null,
"liberation_pct": 100.0,
"contribution_kind": "geld",
"n_shares_subscribed": null,
"contribution_amount_eur": 160000.0
}
],
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": "geld",
"paid_up_delta_eur": 160000.0,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_class_creation",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": "stemgerechtigde",
"n_new_shares": 3340,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_class_creation",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": "stemgerechtigde",
"n_new_shares": 3340,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
}
],
"notary": {
"name": "Katrijn Conjaerts",
"firm_city": null,
"firm_name": null,
"office_city": "Pelt",
"is_associated": false
},
"act_meta": {
"language": "nl",
"pub_date": "2023-11-23",
"filing_date": "2023-11-21",
"act_kind_objet": "Onderwerp akte:"
},
"decision": {
"body": "enig_aandeelhouder_schriftelijk",
"act_date": "2023-11-15",
"unanimous": true,
"under_authorized_capital": false,
"underlying_resolution_date": "2023-11-15"
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0893.010.704",
"name_full": "SCIENCE TRIBUNE",
"legal_form": "Naamloze vennootschap",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"expedition van de akte- geco\u00F6rdineerde statuten"
],
"shareholders_after": [
{
"kbo": null,
"pct": null,
"kind": "person",
"name": "GOOSSENS Peter",
"role": "aandeelhouder",
"n_shares": 3340,
"share_class": "stemgerechtigde"
}
],
"share_classes_after": [
{
"n_shares": 3340,
"class_name": "stemgerechtigde",
"capital_share_eur": 494000.0,
"voting_rights_per_share": 1.0
}
]
}10-11-2022 3 directors appointed
- Inge Berckmans, Bestuurder
- Olaf Beckers, Bestuurder
- Peter Goossens, Gedelegeerd bestuurder
Technical details
{
"events": [
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Inge Berckmans",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": "regular",
"via_org": null,
"statutory": null,
"compensated": false,
"effective_date": null,
"evidence_quote": "",
"decharge_status": null,
"mandate_duration": {
"kind": "n_years",
"value": "6"
},
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": "immediate"
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Olaf Beckers",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": "regular",
"via_org": null,
"statutory": null,
"compensated": false,
"effective_date": null,
"evidence_quote": "",
"decharge_status": null,
"mandate_duration": {
"kind": "n_years",
"value": "6"
},
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": "immediate"
},
{
"kind": "director_in",
"role": "gedelegeerd_bestuurder",
"person": {
"rrn": null,
"name": "Peter Goossens",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": "regular",
"via_org": null,
"statutory": null,
"compensated": null,
"effective_date": null,
"evidence_quote": "",
"decharge_status": null,
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
}
],
"notary": {
"name": null,
"firm_city": null,
"firm_name": null,
"office_city": null,
"is_associated": false
},
"act_meta": {
"language": "nl",
"pub_date": "2022-11-10",
"filing_date": "2022-10-27",
"act_kind_objet": "Onderwerp akte:"
},
"decisions": [
{
"body": "bijzondere_algemene_vergadering",
"date": "2022-09-29",
"unanimous": false
}
],
"is_correction": false,
"subject_company": {
"kbo": "0893.010.704",
"name_full": "Science Tribune",
"legal_form": "NV"
},
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [],
"corrected_publication_numac": null
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameNL | SCIENCE TRIBUNE |